Treatment of Lymphocutaneous Sporotrichosis in Patients Under 18 Years
Pediatric patients under 18 years presenting with cutaneous or lymphocutaneous sporotrichosis require age-specific treatment selection. This protocol addresses that clinical situation directly.
Clinical Scenario
Patient aged under 18 years with confirmed cutaneous or lymphocutaneous sporotrichosis.
Treatment Approach
Oral antifungal therapy is the primary recommended option in this pediatric population, with a distinct oral alternative available when the first-line agent is not appropriate.
Full dosing, thresholds, and sequencing are detailed in the complete protocol →
References
- Itraconazole, administered at a dosage of 6–10 mg/kg up to a maximum of 400 mg orally daily, is recommended for children with cutaneous or lymphocutaneous sporotrichosis (B-III).
- An alternative for children is SSKI therapy, which should be initiated at a dosage of 1 drop (using a standard eye-dropper) 3 times daily and increased as tolerated up to a maximum of 1 drop/kg or 40–50 drops 3 times daily, whichever is lowest (B-III).
DOI: 10.1086/522765
View source ↗